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Hepatitis B virus is the prototype member of the family Hepadnaviridae which 
causes acute and chronic liver diseases worldwide. The viral nucleocapsid 
containing a partially double stranded DNA is surrounded by an envelope 
comprises three distinct but related surface proteins (HBsAg), termed as small 
(S), medium (M) and large (L)-HBsAg. The essential subunit of the nucleocapsid 
is a polypeptide comprising 183 amino acids known as core protein (HBcAg). 
HBcAg produced in Escherichia coli is capable of self-assembly into core-like 
particles and can be purified easily with ammonium sulphate precipitation and 
sucrose gradient centrifugation. Core particles make of full-length HB cAg were 
used as substrate in biopanning with a cysteine constrained phage-displayed 
heptapeptide library. The most frequently identified phage clones displayed the 
cyclic peptides C-WSFFSNI-C and C-WPFWGPW-C. The relative dissociation 
constant (Krl) values for the interaction between the phages and HBcAg were 
determined by an equilibrium binding assay in solution. The Kiel values for 
IV 
phage bearing peptides C-WSFFSNI-C and C-WPFWGPW-C for full-length and 
truncated HBcAg are less than 1 0  and 30 oM, respectively, which are 1 7- and 7-
fold stronger than that of phage bearing the l inear peptide LLGRMK. The 
selected phages were able to compete with monoclonal antibody C 1 -5 for a 
binding site on the surface of core particles, suggesting that the docking site of 
these phages may partial ly overlap with the epitope of mAb C1 -5, which was 
mapped at amino acid positions 78 to 83 at the tips of the core particles. The 
heavy chain of mAb Cl-5 is hydrophobic and was proposed to be the contact 
region for HBcAg. Interestingly, the isolated peptides C-WSFFSNI-C and 
C-WPFWGPW-C are mainly composed of hydrophobic amino acids and may 
bind to the same region as mAb Cl -S. A synthetic linear peptide bearing the 
sequence WSFFSNI inhibited the binding of L-HBsAg to core particles in vitro 
with an inhibition concentration (ICso) approximately 9.8 J.lM. The additional of 
cysteine residues to both the N- and C-termini of the peptide greatly reduced the 
solubil ity of this cyclic peptide, and as a result the ICso is approximately 20-fold 
higher than that of WSFFSNI. A suitable recombinant carrier therefore is needed 
in order to reduce the hydrophobicity of the peptides and subsequently acts as a 
delivery system for targeting the peptide to virally infected cells. 
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Virus Hepatitis B adalah ahli kepada keluarga Hepadnaviridae yang 
menyebabkan masalah kesihatan sedunia serta merupakan punca utama penyakit 
hati kronik dan akut. Nukleokapsid HBV mengandungi DNA bebenang dua 
separa yang diselaputi oleh sarung yang terdiri daripada tiga jenis protein 
permukaan (HBsAg) iaitu HBsAg kecil (S), sederhana (M) dan besar (L). Subunit 
nukleokapsid ini merupakan satu pol ipeptida yang terdiri daripada 1 83 asid amino 
yang dikenal i sebagai protein teras (HBcAg). Unit-unit HBcAg yang dihasilkan 
dalam Escherichia coli bergabung untuk membentuk partikel teras yang boleh 
ditulenkan dengan pemendakan ammonium sulfat dan pengemparan kecerunan 
sukrosa. Partikel teras yang diperbuat daripada HBcAg berpanjangan asal telah 
digunakan sebagai substrat dalam "hiopanning" dengan menggunakan 
perpustakaan peptida pameran faj yang terbatas secara disulfida. Faj-faj yang 
membawa peptida C-WSFFSNI-C dan C-WPFWGPW-C merupakan faj-faj yang 
paling banyak dipilih. Pemalar penceraian relatif (Kiel) antara faj-faj dan HBcAg 
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telah ditentukan dalam asai keseimbangan pengikatan dalam cecair. Nilai-nilai 
Klel bagi faj yang membawa peptida C-WSFFSNI-C dan C-WPFWGPW-C 
dengan HBcAg berpanjangan asal dan bundung adalah kurang daripada 1 0  dan 30  
nM masing-masing, iaitu, 1 7  dan 7 -kali lebih kuat daripada faj yang membawa 
peptida lurus LLGRMK. Faj-faj yang terpilih juga berupaya bersaing dengan 
mAb C 1 -5 untuk tapak pengikatan pada permukaan partikel teras. Penemuan ini  
mencadangkan bahawa tapak pengikatan faj-faj tersebut adalah bertindih secara 
separa dengan epitop mAb CI-5 yang telah dipetakan dalam kedudukan asid 
amino 78 hingga 83 pada penghujung duri partikel teras. Selain daripada itu, 
rantai berat C 1 -5 adalah kaya dengan asid amino yang hidrofobik dan sifat ini 
telah disarankan sebagai bahagian yang bergabung dengan HB cAg. Peptida-
peptida yang terpilih juga terdiri daripada asid amino yang hidrofobik, maka, 
peptida-peptida ini mungkin ikat pada bahagian yang sarna dengan rantai berat 
mAb CI-5. Peptida sintetik lurus WSFFSNI berupaya menyekat pengikatan di 
antara L-HBsAg dan partikel teras secara in vitro dengan kepekatan penyekatan 
(1C50) lebih kurang 9.8 /-lM. Penambahan asid amino sisteina yang bersifat 
hidrofobik pada kedua-dua penghujung C dan N peptida WSFFSNl telah 
menurunkan keterlarutannya, dan seterusnya mengakibatkan lC50 peptida gelang 
ini 20-kali lebih tinggi daripada peptida WSFFSNI. Sesuatu pembawa diperlukan 
untuk mengurangkan hidrofobik peptida-peptida tersebut dan seterusnya 
bertindak sebagai sistem penghantaran peptida-peptida ini ke sel-sel yang 
dijangkiti oleh virus. 
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simian virus 40 
thymine! triangulation number 
tris-buffered EDT A solution 
tris-buffered saline 















AMINO ACID ABBREVIATIONS 








Aspartic acid D Asp 
Cysteine C Cys 
Glutamic acid E Glu 
Glutamine Q GIn 
Glycine G Gly 
Histidine H His 
Isoleucine I lIe 
Leucine L Leu 
Lysine K Lys 
Methionine M Met 
Pheny lalanine F Phe 
Proline P Pro 
Serine S Ser 
Threonine T Thr 
Tryptophan W Trp 
Tyrosine y Tyr 




Hepatitis B virus (HBV) is an enveloped DNA virus of the family 
Hepadnaviridae, which causes a variety of acute and chronic liver diseases such 
as cirrhosis and hepatocellular carcinoma in human and other higher primates 
such as chimpanzees (Ganem and Varmus, 1 987). The virus is transmitted 
through direct contact with serum of an infected patient or body fluid, such as 
saliva, semen and vaginal fluid . In endemic areas, perinatally transmission from 
an HBV -infected mother to her offspring is more common (Mahoney, 1 999). 
Generally, HBV infection becomes clinically apparent in less than 50% of al l 
infected individuals after an incubation period of 35-150 days and a complete 
remission occurs in 90-95% of the cases within 3 to 4 months (Caselmann, 1 996). 
The people infected with HBV either recover from the infection or they may 
remain chronically infected . According to World Health Organisation (WHO), 
there are about 400 mil lion carriers worldwide and approximately 2 million 
carriers die annually (Caselmann, 1996), despite the existence of an effective 
HBV vaccine. 
Currently, there is no safe and effective therapeutic agent treatment available for 
hepatitis B infection. Several inhibitors have been used in the therapy of chronic 
liver d isease such as arabinoside A, acycloguanosine, �- and a-interferon 
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(Bassendine et al., 1 98 1 ;  Weller et al. , 1 983; Thomas and Scully, 1 985). At 
present, a.-interferon appears to hold the best hope to clear the virus. However, 
the overall respond rate is only approximately 50 % (Thomas and Scully, 1 985). 
Lamivudine (also known as 3TC) is the currently l icensed chemotherapeutic, 
which proved to be actively suppressed hepatitis B infection (Hil leman, 200 1 ). 
Until recently, there is no safe and effective antiviral compound against the viral 
assembly and infectivity. To overcome these problems, small molecules such as 
peptide inhibitors, which bind to subunit interfaces that interfere the virus 
morphogenesis have been extensively studied. 
Filamentous bacteriophage displaying millions of random peptide sequences on 
the minor coat proteins has been used to define ligand-binding sites that are 
difficult to identify by conventional methods (Scott and Smith, 1 990). Peptide 
sequences that react with ligands such as monoclonal antibodies (D'Mello et al., 
1997), carbohydrate (Harris et aI., 1 997), virus receptor (Ramanujam et al., 2002) 
and animal organ (Pasqualini and Ruoslahti, 1996) were successfully isolated . 
Peptide sequences that bind to the core antigen ofHBV were successfully isolated 
from a random linear hexapeptide library displayed on gpIII proteins of 
filamentous phage (Dyson and Murray, 1995). The relative dissociation constants 
for the linear hexapeptide and the core particles are in micromolar range. The 
peptides block the association between the core particles and the long surface 
antigen (L-HBsAg) in vitro and also inhibit the virus assembly in cell culture 
system (Dyson and Murray, 1995 ; Bottcher et al., 1 998). The linear peptide 
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sequences were not found as a continuous sequence within the L-HBsAg 
polypeptide, suggesting that some of the amino acids are brought from different 
positions of the polypeptide to form a discontinuous binding region or mimotope. 
Furthermore, Tan et al., ( 1999) showed that the interaction of L-HBsAg and core 
particles is rather complex and involves at least two binding sites. It is therefore 
of interest to select for tighter ligands that bind to these sites with a disulfide 
constrained phage-displayed peptide library. 
Isolation of cyclic peptides that associate with the core particles from a 
conformational phage display peptide library would be advantageous in providing 
high affinity binding clones to the core particles. As a result, synthetic peptides 
based upon the selected sequences would inhibit the association of HBcAg and L­
HBsAg and thus block the assembly of HBV. Therefore, the objectives of this 
study were: 
1 .  To select filamentous phage bearing cyclic peptide sequences that interact 
with HBcAg by biopanning; 
2. To determine the relative dissociation constants (�rel) between the selected 
phages and core particles; 
3 .  To study the binding site ofthe phages on core particles and; 
4. To evaluate the inhibitory effects of the synthetic peptides derived from the 
selected sequences upon the association of core particles and L-HBsAg. 
CHAPTER II 
LITERATURE REVIEW 
2.1 Hepatitis B Virus (HBV) 
2.1 . 1  Hepatitis B Virus Classification 
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HBV is an etiologic agent of human liver diseases, which poses the major public 
health problem, causing acute, chronic and fulminant hepatitis (Tiollais et ai. , 
1981 ) .  HBV is the prototype of the family Hepadnaviridae and subdivided into 
genus Orthohepadnavirus. 
2.1 .2 Epidemiology and Transmission 
HBV is transmitted by exposure to blood or body fluid from HBV-infected 
individuals, and also sexually contact with HBV-infected patients (Mahoney, 
1 999). In the high endemicity areas such as Southeast Asia and China, perinatal 
transmission from infected mother to her offspring and intra-familial spread are 
most common. However, in the moderate and low endemicity areas such as 
United States, Canada, Western Europe, Middle East and Japan, most infections 
occur among the high-risk group for HBV infection such as intravenous drug 
users, sexual contact, haemodialysis patients and occupational exposure to HBV-
